Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology

A.J.M. Ferreri; M. Sassone; P. Angelillo; F. Zaja; A. Re; A. Di Rocco; M. Spina; A. Fabbri; C. Stelitano; M. Frezzato; S. Volpetti; R. Zambello; C. Rusconi; D. De Lorenzo; E. Scarano; A. Arcari; G. Bertoldero; A. Nonis; T. Calimeri; S. Perrone; C. Cecchetti; V. Tarantino; S. Steffanoni; M. Foppoli; F. Ciceri; M. Ponzoni

doi:10.1002/hon.2742

Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology

A.J.M. Ferreri, M. Sassone, P. Angelillo, F. Zaja, A. Re, A. Di Rocco, M. Spina, A. Fabbri, C. Stelitano, M. Frezzato, S. Volpetti, R. Zambello, C. Rusconi, D. De Lorenzo, E. Scarano, A. Arcari, G. Bertoldero, A. Nonis, T. Calimeri, S. PerroneC. Cecchetti, V. Tarantino, S. Steffanoni, M. Foppoli, F. Ciceri, M. Ponzoni

Research output: Contribution to journal › Article › peer-review

Abstract

We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in

Original language	English
Pages (from-to)	257-265
Number of pages	9
Journal	Hematol. Oncol.
Volume	38
Issue number	3
DOIs	https://doi.org/10.1002/hon.2742
Publication status	Published - 2020

Keywords

cell of origin
diffuse large B-cell lymphoma
immunomodulators
lenalidomide
maintenance
transformed high-grade lymphoma
angiogenesis inhibitor
adult
aged
anemia
Article
autologous stem cell transplantation
cancer chemotherapy
cancer immunotherapy
cancer recurrence
clinical article
constipation
diarrhea
diffuse large B cell lymphoma
drug efficacy
drug safety
febrile neutropenia
female
follow up
human
liver toxicity
male
multicenter study
nausea and vomiting
nephrotoxicity
neurotoxicity
neutropenia
phase 2 clinical trial
priority journal
progression free survival
rash
salvage therapy
thrombocytopenia
thrombosis
treatment failure
treatment response
clinical trial
maintenance chemotherapy
middle aged
pathology
prognosis
survival rate
tumor recurrence
very elderly
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Female
Follow-Up Studies
Humans
Lenalidomide
Lymphoma, Large B-Cell, Diffuse
Maintenance Chemotherapy
Male
Middle Aged
Neoplasm Recurrence, Local
Prognosis
Salvage Therapy
Survival Rate

Access to Document

10.1002/hon.2742

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085121372&doi=10.1002%2fhon.2742&partnerID=40&md5=5c3eb2dc324ddf354a607d240e7eb687

Cite this

Ferreri, A. J. M., Sassone, M., Angelillo, P., Zaja, F., Re, A., Di Rocco, A., Spina, M., Fabbri, A., Stelitano, C., Frezzato, M., Volpetti, S., Zambello, R., Rusconi, C., De Lorenzo, D., Scarano, E., Arcari, A., Bertoldero, G., Nonis, A., Calimeri, T., ... Ponzoni, M. (2020). Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology. Hematol. Oncol., 38(3), 257-265. https://doi.org/10.1002/hon.2742

Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation : Hematological Oncology. / Ferreri, A.J.M.; Sassone, M.; Angelillo, P.; Zaja, F.; Re, A.; Di Rocco, A.; Spina, M.; Fabbri, A.; Stelitano, C.; Frezzato, M.; Volpetti, S.; Zambello, R.; Rusconi, C.; De Lorenzo, D.; Scarano, E.; Arcari, A.; Bertoldero, G.; Nonis, A.; Calimeri, T.; Perrone, S.; Cecchetti, C.; Tarantino, V.; Steffanoni, S.; Foppoli, M.; Ciceri, F.; Ponzoni, M.

In: Hematol. Oncol., Vol. 38, No. 3, 2020, p. 257-265.

Research output: Contribution to journal › Article › peer-review

Ferreri, AJM , Sassone, M, Angelillo, P, Zaja, F, Re, A, Di Rocco, A, Spina, M, Fabbri, A, Stelitano, C, Frezzato, M, Volpetti, S, Zambello, R, Rusconi, C, De Lorenzo, D, Scarano, E, Arcari, A, Bertoldero, G, Nonis, A, Calimeri, T, Perrone, S, Cecchetti, C, Tarantino, V, Steffanoni, S, Foppoli, M, Ciceri, F & Ponzoni, M 2020, 'Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology', Hematol. Oncol., vol. 38, no. 3, pp. 257-265. https://doi.org/10.1002/hon.2742

Ferreri, A.J.M. ; Sassone, M. ; Angelillo, P. ; Zaja, F. ; Re, A. ; Di Rocco, A. ; Spina, M. ; Fabbri, A. ; Stelitano, C. ; Frezzato, M. ; Volpetti, S. ; Zambello, R. ; Rusconi, C. ; De Lorenzo, D. ; Scarano, E. ; Arcari, A. ; Bertoldero, G. ; Nonis, A. ; Calimeri, T. ; Perrone, S. ; Cecchetti, C. ; Tarantino, V. ; Steffanoni, S. ; Foppoli, M. ; Ciceri, F. ; Ponzoni, M. / Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation : Hematological Oncology. In: Hematol. Oncol. 2020 ; Vol. 38, No. 3. pp. 257-265.

@article{6b3f5ca7a1334e7eb324ee6d363f7c36,

title = "Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology",

abstract = "We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in ",

keywords = "cell of origin, diffuse large B-cell lymphoma, immunomodulators, lenalidomide, maintenance, transformed high-grade lymphoma, angiogenesis inhibitor, adult, aged, anemia, Article, autologous stem cell transplantation, cancer chemotherapy, cancer immunotherapy, cancer recurrence, clinical article, constipation, diarrhea, diffuse large B cell lymphoma, drug efficacy, drug safety, febrile neutropenia, female, follow up, human, liver toxicity, male, multicenter study, nausea and vomiting, nephrotoxicity, neurotoxicity, neutropenia, phase 2 clinical trial, priority journal, progression free survival, rash, salvage therapy, thrombocytopenia, thrombosis, treatment failure, treatment response, clinical trial, maintenance chemotherapy, middle aged, pathology, prognosis, survival rate, tumor recurrence, very elderly, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Female, Follow-Up Studies, Humans, Lenalidomide, Lymphoma, Large B-Cell, Diffuse, Maintenance Chemotherapy, Male, Middle Aged, Neoplasm Recurrence, Local, Prognosis, Salvage Therapy, Survival Rate",

author = "A.J.M. Ferreri and M. Sassone and P. Angelillo and F. Zaja and A. Re and {Di Rocco}, A. and M. Spina and A. Fabbri and C. Stelitano and M. Frezzato and S. Volpetti and R. Zambello and C. Rusconi and {De Lorenzo}, D. and E. Scarano and A. Arcari and G. Bertoldero and A. Nonis and T. Calimeri and S. Perrone and C. Cecchetti and V. Tarantino and S. Steffanoni and M. Foppoli and F. Ciceri and M. Ponzoni",

note = "Export Date: 11 March 2021 CODEN: HAOND Correspondence Address: Ferreri, A.J.M.; Lymphoma Unit, Italy; email: ferreri.andres@hsr.it Chemicals/CAS: lenalidomide, 191732-72-6; Angiogenesis Inhibitors; Lenalidomide Funding details: Celgene Funding text 1: This trial was partially supported by a grant provided by Celgene Corp. NJ, USA. Lenalidomide was kindly provided by Celgene Corp. NJ, USA. The authors are indebted to our patients and their families for their generous commitment. We also acknowledge hematologists, oncologists, pathologists, and data managers from the 12 participating centers for the sustained collaboration. Neither the sponsor (IRCCS San Raffaele Scientific Institute, Milano, Italy) nor the grant provider had any role in the design, data collection, analysis, results interpretation, and writing of the report.",

year = "2020",

doi = "10.1002/hon.2742",

language = "English",

volume = "38",

pages = "257--265",

journal = "Hematol. Oncol.",

issn = "0278-0232",

publisher = "John Wiley and Sons Ltd",

number = "3",

}

TY - JOUR

T1 - Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation

T2 - Hematological Oncology

AU - Ferreri, A.J.M.

AU - Sassone, M.

AU - Angelillo, P.

AU - Zaja, F.

AU - Re, A.

AU - Di Rocco, A.

AU - Spina, M.

AU - Fabbri, A.

AU - Stelitano, C.

AU - Frezzato, M.

AU - Volpetti, S.

AU - Zambello, R.

AU - Rusconi, C.

AU - De Lorenzo, D.

AU - Scarano, E.

AU - Arcari, A.

AU - Bertoldero, G.

AU - Nonis, A.

AU - Calimeri, T.

AU - Perrone, S.

AU - Cecchetti, C.

AU - Tarantino, V.

AU - Steffanoni, S.

AU - Foppoli, M.

AU - Ciceri, F.

AU - Ponzoni, M.

N1 - Export Date: 11 March 2021 CODEN: HAOND Correspondence Address: Ferreri, A.J.M.; Lymphoma Unit, Italy; email: ferreri.andres@hsr.it Chemicals/CAS: lenalidomide, 191732-72-6; Angiogenesis Inhibitors; Lenalidomide Funding details: Celgene Funding text 1: This trial was partially supported by a grant provided by Celgene Corp. NJ, USA. Lenalidomide was kindly provided by Celgene Corp. NJ, USA. The authors are indebted to our patients and their families for their generous commitment. We also acknowledge hematologists, oncologists, pathologists, and data managers from the 12 participating centers for the sustained collaboration. Neither the sponsor (IRCCS San Raffaele Scientific Institute, Milano, Italy) nor the grant provider had any role in the design, data collection, analysis, results interpretation, and writing of the report.

PY - 2020

Y1 - 2020

N2 - We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in

AB - We report final results of a phase II trial addressing efficacy and feasibility of lenalidomide maintenance in patients with chemosensitive relapse of diffuse large B-cell lymphoma (DLBCL) not eligible for or failed after autologous stem cell transplantation (ASCT). Patients with relapsed DLBCL who achieved at least a partial response to salvage chemoimmunotherapy were enrolled and treated with lenalidomide 25 mg/day for 21 of 28 days for 2 years or until progression or unacceptable toxicity. Primary endpoint was 1-year PFS. Forty-six of 48 enrolled patients were assessable. Most patients had IPI ≥2, advanced stage and extranodal disease before the salvage treatment that led to trial registration; 28 (61%) patients were older than 70 years. Lenalidomide was well tolerated. With the exception of neutropenia, grade-4 toxicities occurred in

KW - cell of origin

KW - diffuse large B-cell lymphoma

KW - immunomodulators

KW - lenalidomide

KW - maintenance

KW - transformed high-grade lymphoma

KW - angiogenesis inhibitor

KW - adult

KW - aged

KW - anemia

KW - Article

KW - autologous stem cell transplantation

KW - cancer chemotherapy

KW - cancer immunotherapy

KW - cancer recurrence

KW - clinical article

KW - constipation

KW - diarrhea

KW - diffuse large B cell lymphoma

KW - drug efficacy

KW - drug safety

KW - febrile neutropenia

KW - female

KW - follow up

KW - human

KW - liver toxicity

KW - male

KW - multicenter study

KW - nausea and vomiting

KW - nephrotoxicity

KW - neurotoxicity

KW - neutropenia

KW - phase 2 clinical trial

KW - priority journal

KW - progression free survival

KW - rash

KW - salvage therapy

KW - thrombocytopenia

KW - thrombosis

KW - treatment failure

KW - treatment response

KW - clinical trial

KW - maintenance chemotherapy

KW - middle aged

KW - pathology

KW - prognosis

KW - survival rate

KW - tumor recurrence

KW - very elderly

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors

KW - Female

KW - Follow-Up Studies

KW - Humans

KW - Lenalidomide

KW - Lymphoma, Large B-Cell, Diffuse

KW - Maintenance Chemotherapy

KW - Male

KW - Middle Aged

KW - Neoplasm Recurrence, Local

KW - Prognosis

KW - Salvage Therapy

KW - Survival Rate

U2 - 10.1002/hon.2742

DO - 10.1002/hon.2742

M3 - Article

VL - 38

SP - 257

EP - 265

JO - Hematol. Oncol.

JF - Hematol. Oncol.

SN - 0278-0232

IS - 3

ER -

Long-lasting efficacy and safety of lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for or failed autologous transplantation: Hematological Oncology

Abstract

Keywords

Access to Document

Fingerprint

Cite this